Vaccination with a mixture
of protamine-complexed
mRNAs could help prevent influenza A infection. A mixture of
protamine-complexed mRNA was formulated that could be stored for three weeks
without loss of efficacy. In both newborn and aged mice, immunization with a
vaccine containing influenza A virus hemagglutinin and influenza
A virus neuraminidase mRNAs resulted in 100% survival against a
lethal influenza virus challenge and no signs of infection, whereas
immunization with a control antigen led to 0% survival. In pigs, immunization
with a related mRNA vaccine that also contained influenza
A virus nucleoprotein (NP)
mRNA prevented signs of clinical disease following influenza virus challenge,
whereas immunization with a control antigen did not. Next steps include
studying the long-term protection conferred by this vaccine approach.CureVac GmbH
has mRNA-based vaccines in preclinical development to prevent undisclosed
infections (see Translating mRNA vaccines, page 1).

Access this BioCentury Innovations article Distillery article for your individual use via a permanent link that allows you to read or print the article: $18.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $18 USDPurchase this article for limited one-time distribution and website posting $750 USD